Latest stories on PLRX
PLRX Wins FDA Fast Track for PLN-101095 Combo in Hard-to-Treat Solid Tumors
MarketChameleon73 · bullishproduct/pr
Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095
The Fly63 · neutralproduct/pr
Pliant Therapeutics reports Q2 EPS (36c), consensus (34c)
The Fly52 · neutralearnings
PLIANT THERAPEUTICS, INC. (PLRX) files 8-K
SEC 8-K50 · neutralgeneral
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Business Insider56 · neutralearnings
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire56 · neutralearnings
Pliant Partners with Coastal to Power U.S. Expansion | CCB Stock News
StockTitan63 · neutralproduct/pr
Pliant Therapeutics adds independent directors to strengthen R&D
TipRanks56 · neutralgeneral
PLIANT THERAPEUTICS, INC. (PLRX) files 8-K
SEC 8-K50 · neutralgeneral
PLIANT THERAPEUTICS, INC. (PLRX) files 8-K
SEC 8-K50 · neutralgeneral
Pliant Therapeutics, Inc. (PLRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Seeking Alpha55 · neutralgeneral